[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603018":3},{"organization":4,"armGroups":7,"interventions":47,"overallOfficials":90,"centralContacts":95,"locations":101,"responsibleParty":120,"collaborators":53,"id":122,"slug":123,"hasResults":124,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":53,"eligibilityCriteria":128,"healthyVolunteers":124,"sex":129,"minAge":130,"maxAge":53,"enrollmentInfo":131,"targetDuration":53,"studyType":134,"phases":135,"briefSummary":137,"conditions":138,"keywords":140,"overallStatus":104,"whyStopped":53,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":151},{"fullName":5,"class":6},"Institute of Hematology & Blood Diseases Hospital, China","OTHER",[8,15,20,24,29,37,42],{"label":9,"type":10,"description":11,"interventionNames":12},"With lDH1 gene mutation","EXPERIMENTAL","Ivosidenib 500mg\u002Fd d1-28 ；Azacitidine 75mg\u002Fm2\u002Fd d1-7；Venetoclax400mg\u002Fd:d1-28",[13,14],"Drug: Ivosidenib","Drug: Venetoclax",{"label":16,"type":10,"description":17,"interventionNames":18},"FLT3 gene mutation","Gilteritinilb 120mg\u002Fd, d1 -28； Venetocax 400mg\u002Fd d1-28 400mg",[19,14],"Drug: Gilteritinib",{"label":21,"type":10,"description":22,"interventionNames":23},"NPM1 mutation or IDH2 mutation","Azacitidine 75mg\u002Fm2\u002Fd d1-7；Venetoclax400mg\u002Fd d1-21 or Cytarabine 20mg\u002Fm2\u002Fd d1-10；Venetoclax 600mg\u002Fd d1-21",[14],{"label":25,"type":10,"description":26,"interventionNames":27},"c-kit mutation","Avapritinib 200mg\u002F day, 28 days a course",[28],"Drug: Avapritinib",{"label":30,"type":10,"description":31,"interventionNames":32},"Daunorubicin\u002FMTZ\u002FIdarubicin+Cytarabine +Venetoclax","Cytarabine 100mg\u002Fm2\u002Fd, d1-5； Daunorubicin 45mg\u002Fm2\u002Fd，d1-2；or Idarubicin 10mg\u002F m2\u002Fd，d1-2；or MTZ 8mg\u002F m2\u002Fd d1-2; Venetoclax 400mg d1-7",[14,33,34,35,36],"Drug: Daunorubicin","Drug: Cytarabine","Drug: Idarubicin","Drug: MTZ",{"label":38,"type":10,"description":39,"interventionNames":40},"Cytarabine+HHT+Venetoclax","Cytarabine 100mg\u002F m2\u002Fd, d1-5; HHT 2mg\u002F m2 d1-5; Venetoclax 400mg d1-7",[14,34,41],"Drug: HHT",{"label":43,"type":10,"description":44,"interventionNames":45},"Venetoclax+Azacitidine\u002FVenetoclax+Cytarabine","Azacitidine75 mg\u002Fm2 day1-7；Venetoclax 400mg day1-21 or，Cytarabine 20mg\u002Fm2 \u002Fday，day1-10； Venetoclax 600mg day1-21",[14,34,46],"Drug: Azacitidine",[48,54,58,62,66,70,74,78,82,86],{"type":49,"name":50,"description":51,"armGroupLabels":52,"otherNames":53},"DRUG","Ivosidenib","500mg d1-28",[9],null,{"type":49,"name":55,"description":56,"armGroupLabels":57,"otherNames":53},"Gilteritinib","120mg d1-28",[16],{"type":49,"name":59,"description":60,"armGroupLabels":61,"otherNames":53},"Venetoclax","400mg d1-21 ; 400mg d1-7;400mg d1-28; 600mg d1-21",[38,30,16,21,43,9],{"type":49,"name":63,"description":64,"armGroupLabels":65,"otherNames":53},"Avapritinib","200mg d1-28.",[25],{"type":49,"name":67,"description":68,"armGroupLabels":69,"otherNames":53},"Daunorubicin","45mg\u002Fm2\u002Fd d1-2;",[30],{"type":49,"name":71,"description":72,"armGroupLabels":73,"otherNames":53},"Cytarabine","100mg\u002Fm2\u002Fd d1-5",[38,30,43],{"type":49,"name":75,"description":76,"armGroupLabels":77,"otherNames":53},"Idarubicin","10mg\u002Fm2\u002Fd d1-2",[30],{"type":49,"name":79,"description":80,"armGroupLabels":81,"otherNames":53},"MTZ","8mg\u002Fm2\u002Fd d1-2",[30],{"type":49,"name":83,"description":84,"armGroupLabels":85,"otherNames":53},"HHT","2mg\u002Fm2\u002Fd d1-5",[38],{"type":49,"name":87,"description":88,"armGroupLabels":89,"otherNames":53},"Azacitidine","75mgd\u002Fm2 d1-7.",[43],[91],{"name":92,"affiliation":93,"role":94},"Huui Wei, doctor","Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College","PRINCIPAL_INVESTIGATOR",[96],{"name":97,"role":98,"phone":99,"phoneExt":53,"email":100},"Hui Wei, Doctor","CONTACT","13132507161","weihui@ihcams.ac.cn",[102],{"facility":103,"status":104,"city":105,"state":106,"zip":107,"country":108,"countryCode":109,"cosmosGeoPoint":110,"geoPoint":115,"contacts":116},"Blood Diseases Hospital","RECRUITING","Tianjin","Tianjin Municipality","300020","China","CN",{"type":111,"coordinates":112},"Point",[113,114],117.17667,39.14222,{"lat":114,"lon":113},[117],{"name":118,"role":98,"phone":119,"phoneExt":53,"email":100},"Hui Wei, MD","86-13132507161",{"type":121,"investigatorFullName":53,"investigatorTitle":53,"investigatorAffiliation":53,"oldNameTitle":53,"oldOrganization":53},"SPONSOR","100603018","mrd-positive-aml-clinical-study-100603018",false,"NCT07131059","MRD-positive AML Clinical Study","MRD-positive AML: a Prospective, Single-arm, Multicenter Platform Clinical Study","Inclusion Criteria:\n\n* AML (non-M3) compliant with WHO (2016) standards;\n* In morphological complete remission.\n* Mrd-positive patients: including bone marrow flow cytometry, PCR quantification of NPM1 mutations, PCR quantification of fusion genes (RUNX 1-RUNX1T1, CBFB-MYH11 and DEK-NUP214), or NGS detection of FLT3 mutation positive.\n* Age over 14 years old, male or female. Informed consent must be signed prior to the commencement of all specific study procedures, and for those 14 years of age and older, informed consent must be signed by the patient or an immediate family member. Considering the patient's condition, if the patient's signature is not conducive to the treatment of the condition, the informed consent shall be signed by the legal guardian or the patient's immediate family.\n\nExclusion Criteria:\n\n* Patients who intend to undergo hematopoietic stem cell transplantation within 4 weeks\n* The diagnosis is APL\n* Those who were not considered suitable for inclusion by the researchers.","ALL","14 Years",{"count":132,"type":133},120,"ESTIMATED","INTERVENTIONAL",[136],"NA","This clinical trial is a platform-type clinical study intended to investigate the efficacy and safety of MRD-positive acute myeloid leukemia patients after comprehensive treatment, which includes but is not limited to the following drugs and protocols: Chemotherapy, small molecule targeted drugs, demethylation drugs, liposome drugs and the combination of these drugs to form a combination of treatment regimen, the specific treatment regimen will be updated according to the results of this trial and the latest research progress at home and abroad.",[139],"AML, Adult",[141],"Measurable Residual Disease","2025-08-18",{"date":144,"type":145},"2025-08-20","ACTUAL",{"date":147,"type":145},"2024-05-11",{"date":149,"type":133},"2028-04-30",{"name":5,"class":6},1]